<< Mitteilung

2019-07-30 07:00

Bone Therapeutics SA: Information on the total number of voting rights and shares

Regulated information


Gosselies, Belgium, 30 July 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares on 10 July 2019 following the conversion of convertible bonds issued on the private placement on 7 March 2018. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.

Total amount of share capital on 1 July 2019EUR 15,540,605
Total number of shares with voting rights on 1 July 201910,303,323
Total number of new shares issued on 10 July 201949,522


Total amount of share capital on 10 July 2019EUR 15,615,383
Total number of shares with voting rights on 10 July 201910,352,845 (a)
Total number of voting rights (denominator) on 10 July 201910,352,845
Total number of attributed warrants210,498
Total number of convertible bonds outstanding257
Total number of bond warrants outstanding1,130
Total number of shares with voting rights that could be created following the exercise of the attributed warrants and the bond warrants, and the conversion of the convertible bonds (1)1,210,411 (b)
Total number of diluted shares with voting rights11,563,256 (a+b)

(1) Based on the conversion price of EUR 3.4678 (92% of the Volume-Weighted-Averaged-Price of Bone Therapeutics on 10 July 2019)


About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an enhanced viscosupplement, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at www.bonetherapeutics.com.


Contacts

Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0) 71 12 10 00
investorrelations@bonetherapeutics.com

International Media Enquiries:
Consilium Strategic Communications
Marieke Vermeersch
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.


Indizes

LU0916829079 644.6793 (-1.79%)

Aktien und Anleihen

Aktie Kurs Letz. +/-
Aperam (EUR) 25.04 25.71 -2.61%
ArcelorMittal (EUR) 15.226 15.606 -2.44%
BlueMarHoldings (EUR) 4.76 4.76 +0.00%
Brederode (EUR) 69.6 70.4 -1.14%
EDIFY act. ord. (EUR) 49.8 49.8 +0.00%
HellaGmbHKGaa (EUR) 44.88 44.94 -0.13%
ImmoLux-Airport (EUR) 266.0 264.0 +0.76%
Luxempart (EUR) 52.0 52.5 -0.95%
RTLGroup (EUR) 45.48 46.8 -2.82%
ReinetInvest (EUR) 14.2 14.2 +0.00%
SEO .prvB (EUR) 260.0 236.0 +10.17%
SEO 1/5prvB (EUR) 54.0 57.0 -5.26%
SES FDR (EUR) 14.89 14.99 -0.67%
SocFinCaoutchcs (EUR) 26.6 26.6 +0.00%
Socfinaf (EUR) 10.3 10.3 +0.00%
Socfinasia (EUR) 12.4 12.2 +1.64%
Vonovia (EUR) 42.11 42.18 -0.17%
Anleihe Kurs Letz. +/-
AXA 5,25% 16/04/2040 (EUR) 102.994 103.034 -0.04%
AirbusFinan 2,375% 02/04/2024 (EUR) 110.681 111.168 -0.44%
AlticeLux 7,25% 15/05/2022 (EUR) 102.455 102.455 +0.00%
Astaldi 7,125% 01/12/2020 (EUR) 21.5 23.5 -8.51%
BASF 2,5% 22/01/2024 (EUR) 110.776 111.262 -0.44%
BNGBank 4,375% 16/02/2021 (USD) 103.379 103.502 -0.12%
BNPParibas 4,875% pp (EUR) 100.295 100.502 -0.21%
BarclaysBank 4,75% pp (EUR) 97.023 97.004 +0.02%
Bayer 1,875% 25/01/2021 (EUR) 102.3 102.29 +0.01%
Bayer 2,375% 02/04/2075 (EUR) 101.455 101.455 +0.00%
Bekaert 5% 06/12/2019 (EUR) 101.047 101.054 -0.01%
BenOldmanESB 10% 23/10/2021 (EUR) 102.0 102.0 +0.00%
Bombardier 6,125% 15/05/2021 (EUR) 106.195 106.14 +0.05%
Bouygues 3,625% 16/01/2023 (EUR) 113.016 113.24 -0.20%
CasinoGuichardP FRN pp (EUR) 42.834 42.561 +0.64%
CmaCgm 7,75% 15/01/2021 Reg S (EUR) 95.387 94.689 +0.74%
Colombia 8,375% 15/02/2027 (USD) 121.25 119.75 +1.25%
CreditAgricole 7,875% pp (EUR) 100.9 100.934 -0.03%
Daimler 2% 25/06/2021 (EUR) 103.7 103.69 +0.01%
DeutscheBank 2% 02/12/2019 (USD) 96.78 96.75 +0.03%
DeutscheBank 2,2% 17/11/2020 (USD) 98.17 98.19 -0.02%
DtscheLufthansa 5,125% 12/08/2075 (EUR) 106.5 106.545 -0.04%
EFSF 1,875% 23/05/2023 (EUR) 108.94 108.94 +0.00%
EFSF 2,25% 05/09/2022 (EUR) 108.5 108.48 +0.02%
ENI 1,75% 18/01/2024 (EUR) 107.72 107.71 +0.01%
GazCapital 8,625% 28/04/2034 (USD) 141.548 141.655 -0.08%
GiePsaTresor 6% 19/09/2033 (EUR) 145.795 145.49 +0.21%
HeidelbergFinLu 7,5% 03/04/2020 (EUR) 104.16 104.155 +0.00%
HornbachBau 3,875% 15/02/2020 (EUR) 101.531 101.57 -0.04%
KfWA 2% 02/05/2025 (USD) 101.34 101.846 -0.50%
Lafarge 4,75% 23/03/2020 (EUR) 102.54 102.545 -0.00%
Luxembourg 2,125% 10/07/2023 (EUR) 111.02 111.015 +0.00%
Luxembourg 2,25% 19/03/2028 (EUR) 121.9 121.99 -0.07%
Luxembourg 2,25% 21/03/2022 (EUR) 107.58 107.59 -0.01%
Luxembourg 2,75% 20/08/2043 (EUR) 143.669 141.305 +1.67%
Luxembourg 3,375% 18/05/2020 (EUR) 102.655 102.66 -0.00%
MOBY 7,75% 15/02/2023 Reg S (EUR) 30.516 30.34 +0.58%
McDonalds 2% 01/06/2023 (EUR) 107.817 108.233 -0.38%
MüchenerRückGes 6% 26/05/2041 (EUR) 110.182 110.352 -0.15%
NBFinanceLtd FRN 07/02/2035 (EUR) 91.647 91.651 -0.00%
NordRheinWFalen 2,375% 16/09/2021 (USD) 100.94 101.112 -0.17%
NovoBanco 100 09/04/2052 (EUR) 22.128 22.199 -0.32%
NovoBanco 3,5% 02/01/2043 (EUR) 99.769 99.227 +0.55%
OMV 6,25% pp (EUR) 127.065 127.11 -0.04%
Pemex 6,5% 02/06/2041 (USD) 93.006 92.477 +0.57%
PetroVenezuela 12,75% 17/02/2022 (USD) 28.7 27.0 +6.30%
PetroVenezuela 5,375% 12/04/2027 (USD) 13.933 13.933 +0.00%
PetroVenezuela 5,5% 12/04/2037 (USD) 13.93 13.93 +0.00%
Philippines 4,2% 21/01/2024 (USD) 108.451 108.593 -0.13%
Portugal 5,125% 15/10/2024 (USD) 113.444 113.802 -0.31%
RWE 3,5% 21/04/2075 (EUR) 108.99 108.99 +0.00%
RWE 6,625% 30/07/2075 (USD) 112.125 112.125 +0.00%
RaiffeisenBkInt 6% 16/10/2023 (EUR) 120.845 120.615 +0.19%
RussianFed 7,5% 31/03/2030 (USD) 120.594 120.558 +0.03%
SNCFMobilites 4,875% 12/06/2023 (EUR) 120.18 120.45 -0.22%
Sanofi 1,75% 10/09/2026 (EUR) 110.932 111.515 -0.52%
StadaArzneimitt 1,75% 08/04/2022 (EUR) 102.28 102.272 +0.01%
SüdzuckIntlFin FRN pp (EUR) 74.373 74.428 -0.07%
TelecomItaliaCa 7,2% 18/07/2036 (USD) 114.254 114.088 +0.15%
TelecomItaliaFi 7,75% 24/01/2033 (EUR) 151.205 151.175 +0.02%
Thyssenkrupp 2,5% 25/02/2025 (EUR) 104.19 104.24 -0.05%
Turkey 7,375% 05/02/2025 (USD) 104.27 104.863 -0.57%
VWIntlFin 4,625% pp (EUR) 110.945 111.285 -0.31%
VWIntlFin 5,125% pp (EUR) 113.205 113.235 -0.03%
Venezuela 11,75% 21/10/2026 (USD) 17.457 19.685 -11.32%
VeoliaEnvironn 6,125% 25/11/2033 (EUR) 174.049 175.814 -1.00%
YPF 8,5% 28/07/2025 Reg S (USD) 77.995 78.378 -0.49%
ØRSTED A/S 6,25% 26/06/3013 (EUR) 120.28 120.28 +0.00%